Phase II, Open-label, Dose-titration, Safety Study Designed to Determine the Evening Dose of a Novel Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) to Produce Optimal Clinical Effects in Children With Attention-Deficit/Hyperactivity Disorder

Trial Profile

Phase II, Open-label, Dose-titration, Safety Study Designed to Determine the Evening Dose of a Novel Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) to Produce Optimal Clinical Effects in Children With Attention-Deficit/Hyperactivity Disorder

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Amfetamine
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions
  • Sponsors Ironshore Pharmaceutical and Development
  • Most Recent Events

    • 12 Apr 2017 According to an Ironshore Pharmaceutical and Development Media Release, results from this trial were reviewed at an End of Phase 2 meeting with the FDA and based on the feedback company is pursuing for two pivotal Phase 3 studies (see profile 276138 and 269841).
    • 12 Apr 2017 According to an Ironshore Pharmaceutical and Development Media Release, results from this trial has been presented to the U.S. Food and Drug Administration.
    • 12 Apr 2017 Results published in the Ironshore Pharmaceutical and Development Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top